NEJM: Novavax recombinant protein vaccine has a protective power of 89.7%, which is effective against the mutant new coronavirus!

At the end of 2020, reports from the United Kingdom, Brazil and South Africa confirmed that the new coronavirus variants B.

NVX-CoV2373 vaccine (Novavax) is composed of 5μg recombinant nanoparticle spike protein and 50μg Matrix-M adjuvant.

Paul T.

After the first and second doses, the vaccine group reported local adverse events more frequently than the placebo group

Among vaccinators, the most frequently reported adverse events were the first dose (53.

The most commonly reported systemic adverse events were headache, muscle pain and fatigue.

Another person who received the vaccine had a serious adverse event (myocarditis), which was 3 days after the second injection.

There are two deaths related to the new crown, one in the vaccine group and one in the placebo group

Among the 14,039 participants, 10 vaccinators and 96 placebo recipients had virologically confirmed, symptomatic mild, moderate, or severe Covid-19 cases, and they were in the second dose At least 7 days after the onset of disease, the vaccine protection is 89.